Immunotherapy plus chemotherapy before surgery for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with limited-stage small-cell lung cancer (the disease is only in one lung and nearby lymph nodes).
- You have not had any prior treatment for this cancer, such as chemotherapy or radiation.
- You have at least one tumor that can be measured on scans.
- You are able to have surgery, chemotherapy, and immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
This trial tests a combination of an immunotherapy drug (benmelstobart) with chemotherapy, and sometimes another drug (anlotinib), for people with limited-stage small cell lung cancer. The goal is to see if this treatment helps shrink or control the cancer before surgery.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.